|
Winter comes, the COVID-19 coronavirus pandemic prevention and control will usher in a new challenge. Recently, CUSABIO has developed a new ELISA kits for the qualitative determination of human novel coronavirus spike glycoprotein RBD (SARS-CoV-2 S RBD) IgG antibody concentrations in serum, plasma.
SARS-CoV-2 S1 RBD IgG is an indicator of a recent or prior COVID infection. Infected patients develop IgG against SARS-CoV-2 S1 RBD 7 days post-infection, and IgG content peaks in the third week (IgM was close to vanishing at this time). IgG lasts in the blood for months or even years. After secondary infection, IgG levels in the body of patients increase rapidly and substantially in the short term and remain in the body for a long time, while IgM rarely increases. Serological testing may help to diagnose suspected patients with negative RT–PCR (real-time polymerase chain reaction) results and identify asymptomatic infections.
The product of CSB-EL33241HU has high sensitivity and excellent specificity for detection of human novel coronavirus spike glycoprotein RBD (SARS-CoV-2 S RBD) IgG antibody. No significant cross-reactivity or interference between human novel coronavirus spike glycoprotein RBD (SARS-CoV-2 S RBD) IgG antibody and analogues was observed.
|
